Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2011 1
2017 1
2019 1
2020 2
2021 4
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Non-SCID combined immunodeficiency"
Page 1
TREC Screening for WHIM Syndrome.
Evans MO 2nd, Petersen MM, Khojah A, Jyonouchi SC, Edwardson GS, Khan YW, Connelly JA, Morris D, Majumdar S, McDermott DH, Walter JE, Murphy PM. Evans MO 2nd, et al. J Clin Immunol. 2021 Apr;41(3):621-628. doi: 10.1007/s10875-020-00921-4. Epub 2021 Jan 7. J Clin Immunol. 2021. PMID: 33415666 Free PMC article.
PURPOSE: T cell receptor excision circle (TREC) quantification is a recent addition to newborn screening (NBS) programs and is intended to identify infants with severe combined immunodeficiencies (SCID). However, other primary immunodeficiency diseases (PID) …
PURPOSE: T cell receptor excision circle (TREC) quantification is a recent addition to newborn screening (NBS) programs and is intended to i …
Advances in basic and clinical immunology in 2010.
Chinen J, Shearer WT. Chinen J, et al. J Allergy Clin Immunol. 2011 Feb;127(2):336-41. doi: 10.1016/j.jaci.2010.11.042. J Allergy Clin Immunol. 2011. PMID: 21281863 Free PMC article. Review.
Reports in basic and clinical immunology in 2010 reflected the use of state-of-the-art genetic and immunologic tools to characterize the pathogenesis of immunologic diseases and the development of novel therapies directed to these conditions. ...Improvement o …
Reports in basic and clinical immunology in 2010 reflected the use of state-of-the-art genetic and immunologic tools to charac …
Infectivity of GII.4 human norovirus does not differ between T-B-NK(+) severe combined immunodeficiency (SCID) and non-SCID gnotobiotic pigs, implicating the role of NK cells in mediation of human norovirus infection.
Annamalai T, Lu Z, Jung K, Langel SN, Tuggle CK, Dekkers JCM, Waide EH, Kandasamy S, Saif LJ. Annamalai T, et al. Virus Res. 2019 Jul 2;267:21-25. doi: 10.1016/j.virusres.2019.05.002. Epub 2019 May 2. Virus Res. 2019. PMID: 31054932 Free PMC article.
Thus, we studied the pathogenesis of human norovirus (HuNoV) in T(-)B(-)NK(+) Severe Combined Immunodeficiency (SCID) gnotobiotic pigs to investigate the role of innate (especially, natural killer (NK) cells) immunity in HuNoV infection. Forty SCID and non- …
Thus, we studied the pathogenesis of human norovirus (HuNoV) in T(-)B(-)NK(+) Severe Combined Immunodeficiency (SCID) gnotobio …
CD3+TCRαβ/CD19+-Depleted Mismatched Family or Unrelated Donor Salvage Stem Cell Transplantation for Graft Dysfunction in Inborn Errors of Immunity.
Ramanathan S, Lum SH, Nademi Z, Carruthers K, Watson H, Flood T, Owens S, Williams E, Hambleton S, Gennery AR, Slatter M. Ramanathan S, et al. Transplant Cell Ther. 2023 Aug;29(8):513.e1-513.e9. doi: 10.1016/j.jtct.2023.05.019. Epub 2023 Jun 4. Transplant Cell Ther. 2023. PMID: 37279857
The median interval between first and second HSCTs was 1.7 years (range, 3 months to 9 years). The primary diagnoses were severe combined immunodeficiency (SCID) (n = 5) and non-SCID IEI (n = 7). ...
The median interval between first and second HSCTs was 1.7 years (range, 3 months to 9 years). The primary diagnoses were severe combined …
Hematopoietic Cell Transplantation for Inborn Errors of Immunity Other than Severe Combined Immunodeficiency in Japan: Retrospective Analysis for 1985-2016.
Miyamoto S, Umeda K, Kurata M, Yanagimachi M, Iguchi A, Sasahara Y, Okada K, Koike T, Tanoshima R, Ishimura M, Yamada M, Sato M, Takahashi Y, Kajiwara M, Kawaguchi H, Inoue M, Hashii Y, Yabe H, Kato K, Atsuta Y, Imai K, Morio T. Miyamoto S, et al. J Clin Immunol. 2022 Apr;42(3):529-545. doi: 10.1007/s10875-021-01199-w. Epub 2022 Jan 4. J Clin Immunol. 2022. PMID: 34981329
We conducted a nationwide study on HCT for patients with IEI other than severe combined immunodeficiency (non-SCID) in Japan. METHODS: Data from the Japanese national database (Transplant Registry Unified Management Program, TRUMP) for 566 patients wit …
We conducted a nationwide study on HCT for patients with IEI other than severe combined immunodeficiency (non-SCID …
Implementation of Universal Newborn Screening for Severe Combined Immunodeficiency in Singapore While Continuing Routine Bacille-Calmette-Guerin Vaccination Given at Birth.
Chan SB, Zhong Y, Lim SCJ, Poh S, Teh KL, Soh JY, Chong CY, Thoon KC, Seng M, Tan ES, Arkachaisri T, Liew WK. Chan SB, et al. Front Immunol. 2022 Jan 3;12:794221. doi: 10.3389/fimmu.2021.794221. eCollection 2021. Front Immunol. 2022. PMID: 35046952 Free PMC article.
INTRODUCTION: Severe Combined Immunodeficiency (SCID) is generally fatal if untreated; it predisposes to severe infections, including disseminated Bacille-Calmette-Guerin (BCG) disease from BCG vaccination at birth. ...RESULTS: Of the 35888 newborns screened in 1 ye …
INTRODUCTION: Severe Combined Immunodeficiency (SCID) is generally fatal if untreated; it predisposes to severe infections, in …
Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.
Nishimura A, Aoki Y, Ishiwata Y, Ichimura T, Ueyama J, Kawahara Y, Tomoda T, Inoue M, Matsumoto K, Inoue K, Hiroki H, Ono S, Yamashita M, Okano T, Tanaka-Kubota M, Ashiarai M, Miyamoto S, Miyawaki R, Yamagishi C, Tezuka M, Okawa T, Hoshino A, Endo A, Yasuhara M, Kamiya T, Mitsuiki N, Ono T, Isoda T, Yanagimachi M, Tomizawa D, Nagasawa M, Mizutani S, Kajiwara M, Takagi M, Kanegane H, Imai K, Morio T. Nishimura A, et al. J Clin Immunol. 2021 Jul;41(5):944-957. doi: 10.1007/s10875-021-00966-z. Epub 2021 Feb 1. J Clin Immunol. 2021. PMID: 33527309
The patients underwent Flu-based RIC-HCT with BU (FluBU: 7 SCID, 16 non-SCID) or Mel (FluMel: 8 SCID, 11 non-SCID). The targeted low-dose BU with therapeutic drug monitoring was set to 30 mg hour/L for SCID. ...Further prospective studies are required …
The patients underwent Flu-based RIC-HCT with BU (FluBU: 7 SCID, 16 non-SCID) or Mel (FluMel: 8 SCID, 11 non-SCID …
Outcome of Non-hematological Autoimmunity After Hematopoietic Cell Transplantation in Children with Primary Immunodeficiency.
Lum SH, Elfeky R, Achini FR, Margarit-Soler A, Cinicola B, Perez-Heras I, Nademi Z, Flood T, Cheetham T, Worth A, Qasim W, Amin R, Rao K, Chiesa R, Bredius RGM, Amrolia P, Abinun M, Hambleton S, Veys P, Gennery AR, Lankester A, Slatter M. Lum SH, et al. J Clin Immunol. 2021 Jan;41(1):171-184. doi: 10.1007/s10875-020-00895-3. Epub 2020 Nov 3. J Clin Immunol. 2021. PMID: 33141919
METHOD: This multicenter retrospective study focuses on incidence, risk factors, and outcomes of post-HCT AD in 596 children with primary immunodeficiency (PID) who were transplanted from 2009 to 2018. RESULTS: The indications of HCT were severe combined immunode …
METHOD: This multicenter retrospective study focuses on incidence, risk factors, and outcomes of post-HCT AD in 596 children with primary …
Outcome of Second Allogeneic HSCT for Patients with Inborn Errors of Immunity: Retrospective Study of 20 Years' Experience.
Mehta P, Tsilifis C, Lum SH, Slatter MA, Hambleton S, Owens S, Williams E, Flood T, Gennery AR, Nademi Z. Mehta P, et al. J Clin Immunol. 2023 Nov;43(8):1812-1826. doi: 10.1007/s10875-023-01549-w. Epub 2023 Jul 14. J Clin Immunol. 2023. PMID: 37452206
Four hundred ninety-three patients underwent allogeneic HSCT for severe combined immunodeficiency (SCID; n = 113, 22.9%) or non-SCID IEI (n = 380, 77.1%). ...
Four hundred ninety-three patients underwent allogeneic HSCT for severe combined immunodeficiency (SCID; n = 113, 22.9%) or …
Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases.
Fernandes JF, Nichele S, Arcuri LJ, Ribeiro L, Zamperlini-Netto G, Loth G, Rodrigues ALM, Kuwahara C, Koliski A, Trennepohl J, Garcia JL, Daudt LE, Seber A, Gomes AA, Fasth A, Pasquini R, Hamerschlak N, Rocha V, Bonfim C. Fernandes JF, et al. Biol Blood Marrow Transplant. 2020 Oct;26(10):1923-1929. doi: 10.1016/j.bbmt.2020.07.003. Epub 2020 Jul 9. Biol Blood Marrow Transplant. 2020. PMID: 32653621 Free article.
Most of the children were male (n = 54) and had active infection at the time of transplantation (n = 50); 10 children had severe organ damage. The diagnosis was severe combined immunodeficiency (SCID) in 34 patients and non-SCID in 39 (Wiskott-Aldrich …
Most of the children were male (n = 54) and had active infection at the time of transplantation (n = 50); 10 children had severe organ damag …
12 results